Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytosorbents Corp (CTSO)

CytoSorbents Q2 revenue flat at $9.6 million; net loss $4.4 million vs prior-year profit

Mixed Impact 3 of 5 earnings Written later

CytoSorbents reported second quarter 2026 results with revenue flat year over year at $9.6 million. Net loss was $4.4 million, or $0.07 per share, compared with net income of $1.9 million, or $0.03 per share, a year earlier; the company attributes the swing mainly to non-cash foreign currency translation changes. Operating loss narrowed 27% to $2.6 million and gross margin rose to 73%, but the balance sheet shows a stockholders' deficit of $0.8 million and $14.1 million of debt classified as current.

Key points

  • Q2 2026 revenue was $9.6 million, unchanged from a year ago; Germany sales fell 24% while distributor and strategic partner sales rose 16%.
  • Net loss was $4.4 million ($0.07 per share) versus net income of $1.9 million ($0.03 per share) in Q2 2025, mainly due to foreign currency effects.
  • Operating loss improved to $2.6 million from $3.6 million, and gross margin rose to 73% from 71% a year ago.
  • Cash, cash equivalents and restricted cash were about $5.9 million at June 30, 2026, versus $6.3 million at March 31, 2026; current debt was $14.1 million.

The filing

CompanyCytosorbents Corp (CTSO)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:19 PM ET
Accession number0001104659-26-092039

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.